公开(公告)号：US11607460B2

公开(公告)日：2023-03-21

申请号：US16226509

申请日：2018-12-19

申请人： SEATTLE GENETICS, INC.

发明人： Timothy S. Lewis ,  Che-Leung Law ,  Julie A. McEarchern

IPC分类号： A61K31/436 ,  A61P35/00 ,  A61K47/68 ,  A61K45/06 ,  A61K31/4375 ,  A61K31/4745 ,  A61K31/498 ,  A61K31/519 ,  A61K31/5377 ,  A61K39/395

摘要： The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway.

公开(公告)号：US11299543B2

公开(公告)日：2022-04-12

申请号：US16306282

申请日：2017-06-01

申请人： Bristol-Myers Squibb Company ,  Seattle Genetics, Inc.

发明人： Benedetto Farsaci ,  Neil Josephson ,  Anthony Cao ,  Ryan Heiser

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K39/395 ,  A61K39/00

摘要： This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD30 antibody. In some embodiments, the tumor is derived from a lymphoma (e.g., a Hodgkin lymphoma or a non-Hodgkin lymphoma). In certain embodiments, the anti-CD30 antibody is an antibody-drug conjugate, e.g., brentuximab vedotin.

公开(公告)号：US20210011021A1

公开(公告)日：2021-01-14

申请号：US16791174

申请日：2020-02-14

申请人： Seattle Genetics, Inc.

发明人： Ana Paula Galvao da Silva ,  Darius Ghaderi ,  Mai Zhang ,  Kristan Meetze ,  Julie DeSander ,  Jeffrey Behrens ,  David A. Eavarone ,  Jillian M. Prendergast

IPC分类号： G01N33/574 ,  C07K16/30 ,  C07K16/44 ,  A61K47/68 ,  C07K16/00

摘要： The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.

公开(公告)号：US20210002380A1

公开(公告)日：2021-01-07

申请号：US16869322

申请日：2020-05-07

申请人： SEATTLE GENETICS, INC.

发明人： Charlotte McDonagh ,  Paul Carter

IPC分类号： C07K16/28

摘要： Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragment or derivative. Also disclosed are methods for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the CD70 binding agents or pharmaceutical compositions.

公开(公告)号：US10808039B2

公开(公告)日：2020-10-20

申请号：US16507839

申请日：2019-07-10

申请人： SEATTLE GENETICS, INC

发明人： Svetlana O. Doronina ,  Peter D. Senter ,  Brian E. Toki ,  Toni Beth Kline

IPC分类号： C07K16/32 ,  C07K7/02 ,  A61K47/68 ,  A61K38/00 ,  A61K39/00

摘要： Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.

公开(公告)号：US20200062857A1

公开(公告)日：2020-02-27

申请号：US16525131

申请日：2019-07-29

申请人： Seattle Genetics, Inc.

发明人： Paul Carter ,  Django Sussman

IPC分类号： C07K16/30 ,  A61K51/10 ,  C07K16/28 ,  A61K47/68

摘要： The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells.

公开(公告)号：US20200030405A1

公开(公告)日：2020-01-30

申请号：US16595430

申请日：2019-10-07

申请人： SEATTLE GENETICS, INC.

发明人： Eric Sievers ,  Dana Kennedy

IPC分类号： A61K38/05 ,  A61K39/00 ,  A61K47/68 ,  C07K16/28 ,  C07K16/30 ,  A61K47/64

摘要： Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.

公开(公告)号：US20200000932A1

公开(公告)日：2020-01-02

申请号：US16489569

申请日：2018-03-02

申请人： SEATTLE GENETICS, INC.

发明人： Daniel T. Dransfield ,  Jillian M. Prendergast ,  David A. Eavarone

IPC分类号： A61K47/68 ,  C07K16/30 ,  A61K38/08 ,  A61K9/00 ,  A61K31/519 ,  A61K31/506 ,  A61K39/395 ,  A61K31/44 ,  A61K31/513 ,  A61K33/243 ,  A61K31/337 ,  A61K31/7068 ,  A61K31/4745 ,  A61P35/00

摘要： Methods of treating cancer are provided that include administering glycan-interacting antibodies. Included are anti-sialyl Tn antigen antibodies and related compositions and formulations suitable to achieve desirable bioactivity, bioavailability, and toxicity levels.

公开(公告)号：US20190388546A1

公开(公告)日：2019-12-26

申请号：US16088235

申请日：2017-03-24

申请人： SEATTLE GENETICS, INC.

发明人： Yunyu Mao ,  Philip Moquist ,  Anusuya Choudhury ,  Wendel Doubleday

IPC分类号： A61K47/54 ,  A61K47/68 ,  A61K47/60 ,  A61K38/07

摘要： The present invention provides improved processes for the preparation of auristatin drug-linkers with a PEG unit, as well as intermediates thereof.

公开(公告)号：US10443035B2

公开(公告)日：2019-10-15

申请号：US15729258

申请日：2017-10-10

申请人： SEATTLE GENETICS, INC.

发明人： Stephen C. Alley ,  Scott C. Jeffrey ,  Django Sussman ,  Dennis R. Benjamin ,  Brian Toki ,  Patrick J. Burke

IPC分类号： C07H3/06 ,  C07H3/02 ,  C07H15/10 ,  C07H19/20 ,  C12N5/00 ,  C07K16/00 ,  C07H13/04

摘要： The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.